Moderna says Covid-19 vaccine immunity to stay at least a year
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BENGALURU] Immunity from Moderna Inc's Covid-19 vaccine should last at least a year, the company said on Monday at the JPMorgan Healthcare conference.
The drugmaker said it was confident that the messenger RNA (mRNA) technology it used was well suited to deploy a vaccine based on the new variant of the coronavirus which has emerged in a handful of countries.
The company's vaccine, mRNA-1273, uses synthetic mRNA to mimic the surface of the coronavirus and teach the immune system to recognise and neutralise it.
Moderna said in December it would run tests to confirm the vaccine's activity against any strain.
The company said on Monday it expects to deliver between 600 million doses and 1 billion does of its vaccine in 2021 and forecast vaccine-related sales of US$11.7 billion for the year, based on advance purchase agreements signed with governments.
"The team feels very comfortable with the track record we have now ... that we are on track to deliver at least 600 million doses," chief executive officer Stéphane Bancel said.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
